Evidence map›Paper›PMID 20177405›Full record

ReviewNature reviews. Cardiology2010

Cell therapy for the treatment of coronary heart disease: a critical appraisal.

Kai C Wollert, Helmut Drexler

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Cardiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed, 4 pooled it
16.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 4 syntheses or guidelines pooled it, 253 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Periprocedural adverse events in cell therapy trials in myocardial infarction and cardiomyopathy: a systematic review.Clinical research in cardiology : official journal of the German Cardiac Society · 2013
    Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Kai C WollertHans-Borst Center for Heart and Stem Cell Research, Department of Cardiology and Angiology, Hannover Medical School, 30625 Hannover, Germany. wollert.kai@mh-hannover.de
Helmut Drexler
Medizinische Hochschule Hannover · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Randomized, controlled clinical trials have demonstrated that cell therapy can improve the recovery of cardiac function in patients after acute myocardial infarction (AMI). Trial results are inconsistent, however, and uncertainty persists regarding the mechanism of action and prospect of cell therapy for patients with heart disease. This Review examines the results from the first-generation trials and discusses procedure-related variables that could have determined treatment outcomes. Obvious issues, including optimal timing of cell transfer, dose, and delivery methods are being investigated in ongoing second-generation trials. These studies aim to refine the protocols and identify the patients who will benefit most from cell therapy. Third-generation trials will address the current limitations of cell therapy, such as cell retention and cell survival after transplantation, and impaired cell functionality in patients with advanced cardiovascular disease. The secretion of factors with paracrine effects by the transplanted cells is an increasingly recognized phenomenon. Identification of these factors, by secretome analyses and bioinformatic approaches, could advance protein-based therapies to promote healing and inhibit pathological remodeling of the heart after AMI. The identification of reliable sources of pluripotent stem cells and their differentiation into mature cardiac cell types could ultimately enable regeneration of the infarcted heart.

Indexed as

Stem Cell TransplantationCoronary Artery DiseaseHumansMultipotent Stem CellsMyocardial InfarctionMyocardial IschemiaParacrine CommunicationPluripotent Stem Cells

Identifiers

PMID20177405
OpenAlexW2085972521

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.